These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 10226086

  • 1. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 2. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ, Cox D, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2000 Nov 04; 295(2):670-6. PubMed ID: 11046104
    [Abstract] [Full Text] [Related]

  • 3. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 04; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 4. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May 04; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 5. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 04; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 6. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug 04; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 7. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 04; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 04; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 9. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 10. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1996 Sep 01; 94(5):906-10. PubMed ID: 8790024
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar 01; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 12. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1997 Aug 19; 96(4):1117-21. PubMed ID: 9286938
    [Abstract] [Full Text] [Related]

  • 13. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Aug 19; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 14. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 15. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 01; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 17. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr 01; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 19. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 20. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Jan 14; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.